Pricing and Reimbursement

The law signed in March 2010 eliminated some of the uncertainty about the future of biosimilars in the US. Still unclear is the impact biosimilars actually will have on costs and when any savings might appear.

Willingness-to-Pay for a New Pharmaceutical: Is it Worth the Money?  Whose  Money?

During this OHE Lunchtime Seminar, Prof Peter Zweifel,...

Europe already has some experience with the impact of biosimilars on pricing, including a price war in Germany for EPOs. Whether that experience will be repeated, however, depends on a number of factors, including the originator's pricing strategy and reservations by payers and physicians about potential risks.

The OHE model varies from other models of biosimilar markets evolution by starting with transaction prices, rather than list prices, and factoring in the collection of 'Patient Safety Year' (PSY) data. These data will capture actual experience with a biosimilar, increasing the comfort level of prescribers and encouraging a gradual increase in market share. PSY data also have important implications for payers and governments, whose options also were outlined in this presentation.

On 16 July, OHE will present a Lunchtime Seminar by Prof Peter Zweifel, who will discuss his recent research on patients' willingness to pay for pharmaceuticals. Space is limited at this seminar.